Risk Stratification in Chronic Lymphocytic Leukemia
The Role of the Clinical Laboratory
CD49d in CLL
November 2008
CD49d is the newest prognostic marker in CLL. It is also known as “alpha 4 integrin” and acts as an adhesion molecule for various extracellular matrix components. It is thought to mediate cell-cell interaction through the binding of VCAM-1, and also is felt to serve as a signaling receptor that influences B-cell survival through the Bcl-2 family.
CD49d in CLL |
Jump to section:
- Introduction
- Goals Today
- Risk Assessment
- Risk Assessment in CLL
- CLL Rai Stage: Treatment Free
- CLL: Nodular Pattern of BM Infiltration
- CLL: Pattern of BM Infiltration
- Blood: Prognostic Indicators
- CLL and Fragile Cells
- CLL: Fragile Cells and Time to Treatment
- CLL Prognostics: CD38
- CLL Rai Stage 0: CD38
- ZAP-70 in B-CLL
- ZAP-70 in B-CLL: Detection
- ZAP-70 in B-CLL: Questions
- ZAP-70 by Flow in CLL
- ZAP-70 by Flow in CLL
- ZAP-70 by Flow in CLL
- ZAP-70: Immunohistochemistry
- CLL Rai Stage 0: ZAP-70
- CD49d in CLL
- CD49d: Clinical Role
- Time to Treatment (TTT) & Overall Survival (OS) from Diagnosis*
- CD49d in CLL
- CD49d in CLL
- Immunoglobulin Variable (IgVH) Region Mutation Status
- IgVH Sequencing
- CLL Rai Stage 0: IgVH
- Chromosome Anomalies in Chronic Lymphocytic Leukemia
- Distribution of Chromosome Anomalies in CLL Detected by FISH
- 13q-: A Microdeletion in B-CLL
- Overall Survival: By FISH Anomaly
- Risk Assessment in CLL: Summary
- Risk Assessment In CLL
- Risk Assessment
- Goals Today
- Questions?
External
link
PDF
document
Excel
document
Word
document